{"id":96944,"date":"2019-11-21T12:51:36","date_gmt":"2019-11-21T11:51:36","guid":{"rendered":"https:\/\/clinical.r-biopharm.com\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/"},"modified":"2026-11-11T13:23:46","modified_gmt":"2026-11-11T12:23:46","slug":"golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen","status":"publish","type":"post","link":"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/","title":{"rendered":"Golimumab: Neue Hoffnung f\u00fcr Patienten mit entz\u00fcndlichen Erkrankungen"},"content":{"rendered":"<div class=\"wpb-content-wrapper\" id=\"wpb-content-root\">[vc_row][vc_column][vc_column_text css=&#8220;.vc_custom_1571985923998{margin-bottom: 0px !important;}&#8220;]<strong>Highly effective and well tolerated: the anti-inflammatory medication golimumab, known under the trade name Simponi\u00ae, is a valuable treatment option for patients with rheumatic diseases as well as chronic inflammatory bowel diseases.<\/strong><!--more--><\/p>\n<p>TNF\u03b1-blockers such as infliximab and adalimumab have significantly improved the treatment options for patients with inflammatory diseases. They are used especially if prior treatments with glucocorticoids or immunosuppressants were unsuccessful. The effectiveness of these biologics is based on a monoclonal antibody, which binds with the tumor necrosis factor (TNF\u03b1). This inhibits TNF\u03b1, which is involved in the origin of inflammations, and the inflammations are decreased. Due to the highly specific binding with TNF\u03b1, TNF\u03b1-blockers also have a more targeted effect than conventional medications.<\/p>\n<p>About ten years ago golimumab expanded the range of the TNF\u03b1-blockers. As the first TNF\u03b1-blocker that only has to be injected once per month, it constitutes a great advantage for patients. It has proven very effective in studies, and it is used successfully to treat the following diseases:[\/vc_column_text][mk_custom_list style=&#8220;mk-icon-chevron-right&#8220;]\n<ul>\n<li><strong>Rheumatoid arthritis<\/strong> \u2013 the most common inflammatory disease of the joints, which affects roughly 0.5\u20131 % of the population worldwide<\/li>\n<li><strong>Psoriasis arthritis<\/strong> \u2013 an inflammatory joint disease that often manifests with psoriasis<\/li>\n<li><strong>Axial spondyloarthritis<\/strong> \u2013 an autoimmune disease that causes inflammation and pain in the spinal column<\/li>\n<li><strong>Ulcerative colitis<\/strong> \u2013 a chronic inflammatory bowel disease that manifests with inflammation and ulcers in the intestinal mucosa<\/li>\n<li><strong>Juvenile idiopathic arthritis<\/strong> \u2013 a rare rheumatic disease that manifests in childhood<\/li>\n<\/ul>\n[\/mk_custom_list][vc_column_text css=&#8220;.vc_custom_1571986000162{margin-bottom: 0px !important;}&#8220;]Golimumab is administered by subcutaneous injection. In order to ensure a successful treatment, the treatmentshould be accompanied by monitoring. Therapeutic medication monitoring is important since due to individual pharmacokinetics the drug level can vary widely from patient to patient in spite of equal dosage. Measurement of the drug level enables the treating physician to supervise the treatment and if needed to optimize it. Hence for long-lasting effectiveness and cost-effectiveness of treatment, medication monitoring is essential.[\/vc_column_text][vc_cta h2=&#8220;Medikamentenmonitoring leicht gemacht&#8220; shape=&#8220;square&#8220; style=&#8220;flat&#8220; add_button=&#8220;right&#8220; btn_title=&#8220;Produktinformation&#8220; btn_style=&#8220;flat&#8220; btn_shape=&#8220;square&#8220; btn_color=&#8220;inverse&#8220; btn_link=&#8220;url:https%3A%2F%2Fclinical.r-biopharm.com%2Fde%2Fprodukte%2Fridascreen%2F|target:%20_blank|&#8220;]The ELISA test <a href=\"https:\/\/clinical.r-biopharm.com\/products\/ridascreen-glm-monitoring\/\">RIDASCREEN\u00ae GLM Monitoring<\/a> is suitable for quantitative analysis of golimumab.[\/vc_cta][\/vc_column][\/vc_row]\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text css=&#8220;.vc_custom_1571985923998{margin-bottom: 0px !important;}&#8220;]Highly effective and well tolerated: the anti-inflammatory medication golimumab, known under the trade name Simponi\u00ae, is a valuable treatment option for patients with rheumatic diseases as well as chronic inflammatory bowel diseases.<\/p>\n","protected":false},"author":14,"featured_media":96948,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[255,239,244,252],"tags":[],"class_list":["post-96944","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-elisa-de","category-gastroenterologie","category-indikation","category-therapeutisches-drug-monitoring"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Golimumab: Neue Hoffnung f\u00fcr Patienten mit entz\u00fcndlichen Erkrankungen<\/title>\n<meta name=\"description\" content=\"Hoch wirksam und gut vertr\u00e4glich: Golimumab (Simponi\u00ae) ist eine wertvolle Therapieoption f\u00fcr Patienten mit rheumatischen Erkrankungen und chronisch-entz\u00fcndlichen Darmerkrankungen.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Golimumab: Neue Hoffnung f\u00fcr Patienten mit entz\u00fcndlichen Erkrankungen\" \/>\n<meta property=\"og:description\" content=\"Hoch wirksam und gut vertr\u00e4glich: Golimumab (Simponi\u00ae) ist eine wertvolle Therapieoption f\u00fcr Patienten mit rheumatischen Erkrankungen und chronisch-entz\u00fcndlichen Darmerkrankungen.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical Diagnostics\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-21T11:51:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-11T12:23:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/09\/TNFalpha-blocker-Therapie-Monitoring.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"690\" \/>\n\t<meta property=\"og:image:height\" content=\"252\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"RalfRechel\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"RalfRechel\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\\\/\"},\"author\":{\"name\":\"RalfRechel\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/#\\\/schema\\\/person\\\/b220bdf72bae67938ba87f282e682ddb\"},\"headline\":\"Golimumab: Neue Hoffnung f\u00fcr Patienten mit entz\u00fcndlichen Erkrankungen\",\"datePublished\":\"2019-11-21T11:51:36+00:00\",\"dateModified\":\"2026-11-11T12:23:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\\\/\"},\"wordCount\":417,\"image\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/wp-content\\\/uploads\\\/2015\\\/09\\\/TNFalpha-blocker-Therapie-Monitoring.jpg\",\"articleSection\":[\"ELISA\",\"Gastroenterologie\",\"Indikation\",\"Therapeutisches Drug Monitoring\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\\\/\",\"url\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\\\/\",\"name\":\"Golimumab: Neue Hoffnung f\u00fcr Patienten mit entz\u00fcndlichen Erkrankungen\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/wp-content\\\/uploads\\\/2015\\\/09\\\/TNFalpha-blocker-Therapie-Monitoring.jpg\",\"datePublished\":\"2019-11-21T11:51:36+00:00\",\"dateModified\":\"2026-11-11T12:23:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/#\\\/schema\\\/person\\\/b220bdf72bae67938ba87f282e682ddb\"},\"description\":\"Hoch wirksam und gut vertr\u00e4glich: Golimumab (Simponi\u00ae) ist eine wertvolle Therapieoption f\u00fcr Patienten mit rheumatischen Erkrankungen und chronisch-entz\u00fcndlichen Darmerkrankungen.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\\\/#primaryimage\",\"url\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/wp-content\\\/uploads\\\/2015\\\/09\\\/TNFalpha-blocker-Therapie-Monitoring.jpg\",\"contentUrl\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/wp-content\\\/uploads\\\/2015\\\/09\\\/TNFalpha-blocker-Therapie-Monitoring.jpg\",\"width\":690,\"height\":252},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Golimumab: Neue Hoffnung f\u00fcr Patienten mit entz\u00fcndlichen Erkrankungen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/\",\"name\":\"Clinical Diagnostics\",\"description\":\"A Division of the R-Biopharm Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/#\\\/schema\\\/person\\\/b220bdf72bae67938ba87f282e682ddb\",\"name\":\"RalfRechel\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b09471782fb6b57a9cf9f676694d1cf670bf5d6c256178907f6529c0ff1996a2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b09471782fb6b57a9cf9f676694d1cf670bf5d6c256178907f6529c0ff1996a2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b09471782fb6b57a9cf9f676694d1cf670bf5d6c256178907f6529c0ff1996a2?s=96&d=mm&r=g\",\"caption\":\"RalfRechel\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Golimumab: Neue Hoffnung f\u00fcr Patienten mit entz\u00fcndlichen Erkrankungen","description":"Hoch wirksam und gut vertr\u00e4glich: Golimumab (Simponi\u00ae) ist eine wertvolle Therapieoption f\u00fcr Patienten mit rheumatischen Erkrankungen und chronisch-entz\u00fcndlichen Darmerkrankungen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/","og_locale":"de_DE","og_type":"article","og_title":"Golimumab: Neue Hoffnung f\u00fcr Patienten mit entz\u00fcndlichen Erkrankungen","og_description":"Hoch wirksam und gut vertr\u00e4glich: Golimumab (Simponi\u00ae) ist eine wertvolle Therapieoption f\u00fcr Patienten mit rheumatischen Erkrankungen und chronisch-entz\u00fcndlichen Darmerkrankungen.","og_url":"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/","og_site_name":"Clinical Diagnostics","article_published_time":"2019-11-21T11:51:36+00:00","article_modified_time":"2026-11-11T12:23:46+00:00","og_image":[{"width":690,"height":252,"url":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/09\/TNFalpha-blocker-Therapie-Monitoring.jpg","type":"image\/jpeg"}],"author":"RalfRechel","twitter_misc":{"Verfasst von":"RalfRechel","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/#article","isPartOf":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/"},"author":{"name":"RalfRechel","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/b220bdf72bae67938ba87f282e682ddb"},"headline":"Golimumab: Neue Hoffnung f\u00fcr Patienten mit entz\u00fcndlichen Erkrankungen","datePublished":"2019-11-21T11:51:36+00:00","dateModified":"2026-11-11T12:23:46+00:00","mainEntityOfPage":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/"},"wordCount":417,"image":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/#primaryimage"},"thumbnailUrl":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/09\/TNFalpha-blocker-Therapie-Monitoring.jpg","articleSection":["ELISA","Gastroenterologie","Indikation","Therapeutisches Drug Monitoring"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/","url":"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/","name":"Golimumab: Neue Hoffnung f\u00fcr Patienten mit entz\u00fcndlichen Erkrankungen","isPartOf":{"@id":"https:\/\/clinical.r-biopharm.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/#primaryimage"},"image":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/#primaryimage"},"thumbnailUrl":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/09\/TNFalpha-blocker-Therapie-Monitoring.jpg","datePublished":"2019-11-21T11:51:36+00:00","dateModified":"2026-11-11T12:23:46+00:00","author":{"@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/b220bdf72bae67938ba87f282e682ddb"},"description":"Hoch wirksam und gut vertr\u00e4glich: Golimumab (Simponi\u00ae) ist eine wertvolle Therapieoption f\u00fcr Patienten mit rheumatischen Erkrankungen und chronisch-entz\u00fcndlichen Darmerkrankungen.","breadcrumb":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/#primaryimage","url":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/09\/TNFalpha-blocker-Therapie-Monitoring.jpg","contentUrl":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/09\/TNFalpha-blocker-Therapie-Monitoring.jpg","width":690,"height":252},{"@type":"BreadcrumbList","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/golimumab-neue-hoffnung-fur-patienten-mit-entzundlichen-erkrankungen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clinical.r-biopharm.com\/de\/"},{"@type":"ListItem","position":2,"name":"Golimumab: Neue Hoffnung f\u00fcr Patienten mit entz\u00fcndlichen Erkrankungen"}]},{"@type":"WebSite","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#website","url":"https:\/\/clinical.r-biopharm.com\/fr\/","name":"Clinical Diagnostics","description":"A Division of the R-Biopharm Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clinical.r-biopharm.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/b220bdf72bae67938ba87f282e682ddb","name":"RalfRechel","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/b09471782fb6b57a9cf9f676694d1cf670bf5d6c256178907f6529c0ff1996a2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b09471782fb6b57a9cf9f676694d1cf670bf5d6c256178907f6529c0ff1996a2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b09471782fb6b57a9cf9f676694d1cf670bf5d6c256178907f6529c0ff1996a2?s=96&d=mm&r=g","caption":"RalfRechel"}}]}},"_links":{"self":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/96944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/comments?post=96944"}],"version-history":[{"count":4,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/96944\/revisions"}],"predecessor-version":[{"id":183250,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/96944\/revisions\/183250"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/media\/96948"}],"wp:attachment":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/media?parent=96944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/categories?post=96944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/tags?post=96944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}